TELA Bio (TELA) Free Cash Flow Growth (3y) (2021 - 2026)
TELA Bio (TELA) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | 41.96% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 25.48% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 0.05% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 35.42% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | 250.09% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 12.01% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 35.65% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 20.87% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 9.23% |
| 10 | TELA Bio | 36.24 Mn | 5.82 Mn | 13.94 Mn | 6.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.15% |
| Mar 31, 2026 | 1.15% |
| Dec 31, 2025 | 21.26% |
| Sep 30, 2025 | 10.71% |
| Jun 30, 2025 | 11.31% |
| Mar 31, 2025 | 3.23% |
| Dec 31, 2024 | 4.75% |
| Sep 30, 2024 | -10.87% |
| Jun 30, 2024 | -23.21% |
| Mar 31, 2024 | -19.15% |
| Dec 31, 2023 | -15.54% |
| Sep 30, 2023 | -25.31% |
| Jun 30, 2023 | -20.61% |
| Mar 31, 2023 | -16.59% |
| Dec 31, 2022 | -12.09% |
| Sep 30, 2022 | -15.31% |
| Jun 30, 2022 | -29.89% |
| Mar 31, 2022 | -11.22% |
| Dec 31, 2021 | -18.63% |